Tokyo, Aug. 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062587) titled 'Research investigating how the brain works when we smell' on Aug. 16.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Osaka metropolitan university

Condition: Condition - olfactory disfunction Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To clarify the brain activity involved when humans consciously perceive odors Basic objectives2 - Others

Intervention: Interventions/Control_1 - The reagents used in olfactory testing are classified as pharmaceuticals. These include beta-Phenylethyl alcohol, Methyl cyclopentenolone, Isovaleric acid, ganma-undecalactone, and Skatole.

Two of the following reagents are used during the preliminary olfactory test and MEG measurement: beta-Phenylethyl alcohol, Methyl cyclopentenolone, and ganma-undecalactone.

Eligibility: Age-lower limit - 18 years-old = Gender - Male and Female Key inclusion criteria - Individuals who meet all of the following selection criteria and do not meet any of the exclusion criteria will be included as research participants in this study.

1. Individuals who have the willingness and ability to provide informed consent of their own free will. 2. Individuals who have given written consent to participate in the study. 3. Individuals aged 18 to 40 years at the time of obtaining consent. 4. Individuals with normal olfactory function (average recognition threshold of 1.0 or less) as measured by the standard olfactory function test. Key exclusion criteria - Individuals who are pregnant or planning to become pregnant at the time of obtaining consent. Individuals with abnormal findings in the nasal cavity. Individuals unsuitable for MRI scans or magnetoencephalography measurements. Individuals with metal implants in their bodies, cardiac pacemakers, artificial heart valves, cochlear implants/middle ears, non-titanium brain aneurysm clips, artificial joints, bolt fixation for fractures, magnetic dentures or other magnetic materials implanted in the body, implants, orthodontic appliances, tattoos, permanent makeup, IUDs, or metal in the eyes Individuals with claustrophobia. Individuals with a history of hyperventilation. Target Size - 20

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 07 Month 24 Day Anticipated trial start date - 2026 Year 08 Month 16 Day Last follow-up date - 2030 Year 08 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071469

Disclaimer: Curated by HT Syndication.